Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Thu, 03 Sep 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16^th European Epilepsy Congress being held from September 5-9, in Athens, Greece.

The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are currently enrolling, and more information can be found at argustrial.com and lighthouselgsstudy.com.

Poster presentation details are listed below:

argustrial.com and lighthouselgsstudy.com.

Poster presentation details are listed below:

https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs.

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Thu, 27 Aug 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

Wolfe Research Starts Harmony Biosciences Holdings Inc. (HRMY) at Outperform

Wed, 26 Aug 2026 05:32:48 -0400

Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) with a Outperform rating and a price target of $60.00.

The analyst comments "HRMY has established itself as a key player in the sleep space with its lead asset Wakix. While investors are debating the ongoing IP litigation and competitive threat from orexin agonists, we expect the Wakix franchise to remain resilient: ● Wakix is approved in 2019 for narcolepsy - Its unique profile has drawn mixed KOL feedback, but still on track to $1B sales in 2026 (~20% growth YoY). ● The Wakix franchise provides strong

Wolfe Research Starts Harmony Biosciences Holdings Inc. (HRMY) at Outperform

Wed, 26 Aug 2026 05:32:48 -0400

Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) with a Outperform rating and a price target of $60.00.

Form 144 Harmony Biosciences Hold Filed by: Valor IV Pharma Holdings, LLC

Fri, 07 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260807/26891862.html

Form 144 Harmony Biosciences Hold Filed by: Valor IV Pharma Holdings, LLC

Fri, 07 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260807/26891862.html

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Thu, 06 Aug 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Thu, 06 Aug 2026 08:05:00 -0400

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Tue, 04 Aug 2026 14:30:23 -0400

(Updated - August 4, 2026 2:30 PM EDT)

Oppenheimer analyst Andreas Argyrides lowered the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $70.00 (from $85.00) while maintaining a Outperform rating.

The analyst commented: "HRMY reported impressive 2Q26 results with Wakix net sales of $261.3M (+30% y/y) exceeding the $250.8M consensus estimate, supporting maintained FY26 guidance of $1.00-1.04B. We see the new Ph1 SAD data for BP-205 (orexin-2 agonist) as supporting a best-in-class profile. Specifically, BP-205 demonstrated potential for once-daily dosing, high selectivity, and no serious safety signals, which notably enables potential utility across broad indications. We anticipate upcoming Ph1 MAD

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Tue, 04 Aug 2026 14:30:23 -0400

(Updated - August 4, 2026 2:30 PM EDT)

Oppenheimer analyst Andreas Argyrides lowered the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $70.00 (from $85.00) while maintaining a Outperform rating.

Form 10-Q Harmony Biosciences Hold For: Jun 30

Tue, 04 Aug 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260804/26862214.html

Form 10-Q Harmony Biosciences Hold For: Jun 30

Tue, 04 Aug 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260804/26862214.html

Form 8-K Harmony Biosciences Hold For: Aug 04

Tue, 04 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26862091.html

Form 8-K Harmony Biosciences Hold For: Aug 04

Tue, 04 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26862091.html

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Tue, 04 Aug 2026 07:30:00 -0400

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026

BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027

Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Tue, 04 Aug 2026 07:30:00 -0400

Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026

BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027

Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $51 at Mizuho

Mon, 03 Aug 2026 06:36:49 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $51.00 (from $50.00) while maintaining a Outperform rating.

Form SCHEDULE 13G Harmony Biosciences Hold Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260731/26848769.html

Form SCHEDULE 13G Harmony Biosciences Hold Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260731/26848769.html

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $51 at Mizuho

Fri, 31 Jul 2026 06:53:39 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $51.00 (from $50.00) while maintaining a Outperform rating.

Form SCHEDULE 13G/A Harmony Biosciences Hold Filed by: BlackRock, Inc.

Tue, 28 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260728/26827986.html

Form SCHEDULE 13G/A Harmony Biosciences Hold Filed by: BlackRock, Inc.

Tue, 28 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260728/26827986.html

Form 3 Harmony Biosciences Hold For: Jul 16 Filed by: Mollichella Stephen M.

Wed, 22 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26801541.html

StreetInsider.com News Articles

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Wolfe Research Starts Harmony Biosciences Holdings Inc. (HRMY) at Outperform

Wolfe Research Starts Harmony Biosciences Holdings Inc. (HRMY) at Outperform

Form 144 Harmony Biosciences Hold Filed by: Valor IV Pharma Holdings, LLC

Form 144 Harmony Biosciences Hold Filed by: Valor IV Pharma Holdings, LLC

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Form 10-Q Harmony Biosciences Hold For: Jun 30

Form 10-Q Harmony Biosciences Hold For: Jun 30

Form 8-K Harmony Biosciences Hold For: Aug 04

Form 8-K Harmony Biosciences Hold For: Aug 04

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $51 at Mizuho

Form SCHEDULE 13G Harmony Biosciences Hold Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Form SCHEDULE 13G Harmony Biosciences Hold Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $51 at Mizuho

Form SCHEDULE 13G/A Harmony Biosciences Hold Filed by: BlackRock, Inc.

Form SCHEDULE 13G/A Harmony Biosciences Hold Filed by: BlackRock, Inc.

Form 3 Harmony Biosciences Hold For: Jul 16 Filed by: Mollichella Stephen M.